Resmed Inc
RSMDF- Exchange
- OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000943819
In the last 90 days, Resmed Inc insiders filed 0 open-market purchases and 5 sales; 1 institution reported holding it in 13F filings for Q2 2026, worth $1.17K in total; no superinvestor holds it.
Other share classesRMD
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $5.26M in total
- 5
- 13F holdersQ2 2026, 0 vs. previous quarter
- 1
- 13F valueReported value at the end of Q2 2026
- $1.17K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding RSMDF, Q2 2026
No superinvestor reported holding RSMDF at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Resmed Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 (view filing)6:40 AM ET | Sep 8 | 2 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $222.44 | −$1.11M | −1.1%466.3K after | 10b5-1 |
| Sep 4, 2026 (view filing)6:30 AM ET | Sep 2 | 2 days | Farrell Peter CDirector | SSaleResMed Common Stock | −970 | $234.73 | −$227.7K | −1.8%51.8K after | 10b5-1 |
| Aug 11, 2026 (view filing)6:30 AM ET | Aug 7 | 4 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $205.69 | −$1.03M | −1.1%466.3K after | 10b5-1 |
| Aug 6, 2026 (view filing)2:29 PM ET | Aug 5 | 1 day | Farrell Peter CDirector | SSaleResMed Common Stock | −8.00K | $225.00 | −$1.80M | −13.2%52.8K after | 10b5-1 |
| Jul 9, 2026 (view filing)7:40 AM ET | Jul 7 | 2 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $218.55 | −$1.09M | −1.1%466.2K after | 10b5-1 |
| Jun 9, 2026 (view filing) | Jun 8 | 1 day | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $193.96 | −$968.1K | −1.1%466.3K after | 10b5-1 |
| May 11, 2026 (view filing) | May 7 | 4 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $207.82 | −$1.04M | −1.1%466.2K after | 10b5-1 |
| Apr 9, 2026 (view filing) | Apr 7 | 2 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $225.50 | −$1.13M | −1.1%466.2K after | 10b5-1 |
| Apr 3, 2026 (view filing) | Apr 1 | 2 days | Sandercock BrettChief Financial Officer | SSaleResMed Common Stock | −1.00K | $224.31 | −$224.3K | −1.2%83.5K after | 10b5-1 |
| Apr 2, 2026 (view filing) | Apr 1 | 1 day | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $225.00 | −$450.0K | −3.2%60.8K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Resmed Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| GAMMA Investing LLC | 70 | $1.17K | 0.00% | −2,722−97.5% | Reduced |